Medical Apps for Cardiology Uses. There s an App for That!

Size: px
Start display at page:

Download "Medical Apps for Cardiology Uses. There s an App for That!"

Transcription

1 Medical Apps for Cardiology Uses There s an App for That!

2

3

4 Audience Participation Question #1 1. ASCVD Risk App What is the predicted 10 year CV event rate for a 57 y/o black male patient with treated BP of 150/85 and total cholesterol 180 and HDL cholesterol of 35? (Remember statin recommended if the 10 year CV event risk above 7.5%?) A. 4% B. 8% C. 13% D. 17%

5 Audience Participation Question #1 1. ASCVD Risk App What is the predicted 10 year CV event rate for a 57 y/o black male patient with treated BP of 150/85 and total cholesterol 180 and HDL cholesterol of 35? (Remember statin recommended if the 10 year CV event risk above 7.5%?) A. 4% B. 8% C. 13% D. 17%

6

7

8

9

10

11 Audience Participation Question #2 ASCVD Risk App What is the 10 year CV event rate for a white female with the same parameters (age 57, treated BP 150/85, total cholesterol 180, HDL 35)? A. 4% B. 8% C. 13% D. 17%

12 Audience Participation Question #2 ASCVD Risk App What is the 10 year CV event rate for a white female with the same parameters (age 57, treated BP 150/85, total cholesterol 180, HDL 35)? A. 4% B. 8% C. 13% D. 17%

13

14

15

16 2. STATATP III App How different is the new ASCVD risk calculator from the previous ATP III risk assessment?

17

18

19

20

21

22

23 Audience Participation Question #3 3. MedCalc App What is the CHA2DS2-VASC Score and annual stroke risk for a 76 y/o female patient with atrial fibrillation,hypertension & CHF with chronic renal insufficiency before anticoagulation? CHA2DS2-VASC Score A. 2 3% B. 3 4% C. 4 5% D. 5 7% annual stroke risk

24 Audience Participation Question #3 3. MedCalc App What is the CHA2DS2-VASC Score and annual stroke risk for a 76 y/o female patient with atrial fibrillation, hypertension & CHF with chronic renal insufficiency before anticoagulation? CHA2DS2-VASC Score A. 2 3% B. 3 4% C. 4 5% D. 5 7% annual stroke risk

25

26

27

28

29

30

31 Audience Participation Question #4 4. ACC Anticoag Evaluator What is the predicted annual stroke risk vs major bleeding risk in this same 76y/o female patient with atrial fibrillation, hypertension, CHF, and chronic renal insufficiency if she is treated with warfarin? Annual stroke risk major bleeding risk A. 2% 2% B. 3% 6% C. 5% 3% D. 8% 1%

32 Audience Participation Question #4 4. ACC Anticoag Evaluator What is the predicted annual stroke risk vs major bleeding risk in this same 76y/o female patient with atrial fibrillation, hypertension, CHF, and chronic renal insufficiency if she is treated with warfarin? Annual stroke risk major bleeding risk A. 2% 2% B. 3% 6% C. 5% 3% D. 8% 1%

33

34

35

36

37

38

39

40 Audience Participation Question #5 4. ACC Anticoag Evaluator What is the predicted annual stroke risk vs major bleeding risk in this same 76y/o female patient with atrial fibrillation, hypertension, CHF, and chronic renal insufficiency if she is treated with aspirin alone? Annual stroke risk major bleeding risk A. 2% 2% B. 3% 6% C. 5% 3% D. 8% 1%

41 Audience Participation Question #5 4. ACC Anticoag Evaluator What is the predicted annual stroke risk vs major bleeding risk in this same 76y/o female patient with atrial fibrillation, hypertension, CHF, and chronic renal insufficiency if she is treated with aspirin alone? Annual stroke risk major bleeding risk A. 2% 2% B. 3% 6% C. 5% 3% D. 8% 1%

42

43

44 5. AUC Nuclear Should I order a stress nuclear scan on my patient with history of CHF who cannot exercise who is seen in pre-op evaluation before hip surgery? Should I order a stress nuclear scan on my patient who suffered a non-stemi 2 months ago and no chest pain since?

45

46

47

48

49

50

51

52

53 5. AUC Nuclear Should I order a stress nuclear scan on my patient with history of CHF who cannot exercise who is seen in pre-op evaluation before hip surgery? Should I order a stress nuclear scan on my patient who suffered a non-stemi 2 months ago and no chest pain since?

54

55

56

57

58

59

60 5. AUC Nuclear Should I order a stress nuclear scan on my patient who suffered a non-stemi 2 months ago and no chest pain since? What if 6 months post non-stemi and no chest pain since?

61

62 6. AUC Echo Should I order an echocardiogram on my patient with mild aortic valve stenosis on last echocardiogram 2 ½ years ago without new symptoms? Or on my patient with moderate aortic valve stenosis on last echocardiogram 1 year ago without new symptoms? Or on my patient with history of mitral valve replacement 2 years ago without new symptoms?

63

64

65

66

67

68

69

70

71 AUC Echo Should I order an echocardiogram on my patient with mild aortic valve stenosis on last echocardiogram 2 ½ years ago without new symptoms? Or on my patient with moderate aortic valve stenosis on last echocardiogram 1 year ago without new symptoms? Or on my patient with history of mitral valve replacement 2 years ago without new symptoms?

72

73

74

75 AUC Echo Should I order an echocardiogram on my patient without new symptoms with mild aortic valve stenosis on last echocardiogram 2 ½ years ago? Or on my patient without symptoms with moderate aortic valve stenosis on last echocardiogram 1 year ago? Or on my patient with history of mitral valve replacement 2 years ago without new symptoms?

76

77

78

79

80

81 Audience Participation Question #6 7. Seattle HF App What is the predicted 5 year survival for a 72 year old man weighting 80 kg with ischemic heart disease, systolic BP 110, with class 2-3 CHF and LVEF 0.35 without treatment? A. 33% B. 44% C. 55% D. 66%

82 Audience Participation Question #6 7. Seattle HF App What is the predicted 5 year survival for a 72 year old man weighting 80 kg with ischemic heart disease, systolic BP 110, with class 2-3 CHF and LVEF 0.35 without treatment? A. 33% B. 44% C. 55% D. 66%

83 7. Seattle HF App How much is my CHF patient s risk reduced by treatments with beta blocker, ACE inhibitor, spironolactone, and defibrillator? Example: 72 year-old man with blood pressure 110/70, LVEF 0.35, ischemic heart disease, and newly diagnosed class 2-3 CHF

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for

More information

Peripheral Arterial Disease Medical Approach and Management

Peripheral Arterial Disease Medical Approach and Management Peripheral Arterial Disease Medical Approach and Management April 2, 2016 Michael F. Hagerty, MD FACC PAD: Classic and New Concepts Let s take a look at what s new and what s old or classic in 2016. PAD:

More information

Atrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018

Atrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018 Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%

More information

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information

Quality Measures MIPS CV Specific

Quality Measures MIPS CV Specific Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from

More information

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer

More information

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17 2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor

More information

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding

More information

Update in the Literature 2012

Update in the Literature 2012 Update in the Literature 2012 Mel L. Anderson, MD, FACP Chief, Hospital Medicine Section Associate Chief, Medical Service Denver VA Medical Center Associate Professor of Medicine University of Colorado

More information

Patient Encounters in the Primary Care Setting

Patient Encounters in the Primary Care Setting Patient Encounters in the Primary Care Setting Carmine D Amico, D.O. Clinical Cases Overview Learning objectives Clinical case presentations Questions for audience participation 1 Clinical Cases Learning

More information

Atrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology

Atrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED

More information

SONOGRAPHER & NURSE LED VALVE CLINICS

SONOGRAPHER & NURSE LED VALVE CLINICS SONOGRAPHER & NURSE LED VALVE CLINICS Frequency of visits and alerts AORTIC STENOSIS V max > 4.0 m/s or EOA < 1.0 cm 2 V max 3.5 4.0 m/s + Ca+ V max 3.0 4.0 m/s or EOA 1.0-1.5 cm 2 V max 2.5 3.0 m/s every

More information

Cost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib

Cost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million

More information

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

RF & RHD Workshop 22 nd March MANAGEMENT of RHEUMATIC HEART DISEASE in PREGNANCY. Dr Dorothy Radford

RF & RHD Workshop 22 nd March MANAGEMENT of RHEUMATIC HEART DISEASE in PREGNANCY. Dr Dorothy Radford RF & RHD Workshop 22 nd March 2016 MANAGEMENT of RHEUMATIC HEART DISEASE in PREGNANCY Dr Dorothy Radford PREGNANCY PHYSIOLOGY Increased cardiac output 30%-50% Increased blood volume 30%-50% Increased heart

More information

Conflict of interest statement

Conflict of interest statement Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial J.J.V. McMurray 1, B. Lewis

More information

Update in Cardiology What s Hot in 2017?

Update in Cardiology What s Hot in 2017? Update in Cardiology What s Hot in 2017? Mark R. Milunski, MD, FACC, FACP Chief, Cardiology Section Orlando Veterans Affairs Medical Center Associate Professor of Medicine University of Central Florida

More information

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)

More information

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships

More information

Controversies in Atrial Fibrillation and HF

Controversies in Atrial Fibrillation and HF Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.

More information

Primary Prevention of Stroke

Primary Prevention of Stroke Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for

More information

Practice-Level Executive Summary Report

Practice-Level Executive Summary Report PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular

More information

VanderbiltEM.com. Atrial Fibrillation Update Don t Miss a Beat ACEP Atrial Fibrillation is Common

VanderbiltEM.com. Atrial Fibrillation Update Don t Miss a Beat ACEP Atrial Fibrillation is Common Atrial Fibrillation Update Don t Miss a Beat ACEP 2016 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN VanderbiltEM.com

More information

2016 Internal Medicine Preferred Specialty Measure Set

2016 Internal Medicine Preferred Specialty Measure Set 1 0059 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%): Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period 5 0081 Registry, EHR, 9 0105

More information

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Consensus Core Set: Cardiovascular Measures Version 1.0

Consensus Core Set: Cardiovascular Measures Version 1.0 Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized

More information

Atrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018

Atrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne

More information

Atrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today

Atrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today

More information

MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?

MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE

More information

An EMR Specifically Designed for the Cardiovascular Practice

An EMR Specifically Designed for the Cardiovascular Practice An EMR Specifically Designed for the Cardiovascular Practice Gary Chaisson RTR, RCSA Co-Founder Objective Medical Systems May 30, 2017 Disclosure Major Shareholder Objective Medical Systems EMR History

More information

Cardiac Perioperative Risk Assessment American Heart Association Guidelines

Cardiac Perioperative Risk Assessment American Heart Association Guidelines Cardiac Perioperative Risk Assessment American Heart Association Guidelines Dr Gary Liew, MBBS, PhD, FRACP US Board Certified in Cardiovascular CT Executive Committee, Cardiac Institute, Epworth Healthcare

More information

NOACs in AF. Dr Fiona Stewart. Auckland Heart Group and Auckland DHB

NOACs in AF. Dr Fiona Stewart. Auckland Heart Group and Auckland DHB NOACs in AF Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACS for AF True/False All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF NOACS are more effective than warfarin

More information

1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare?

1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare? 1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare? Dr Nerys Davies, GPST Ms B. Davies, Specialist Nurse (Heart Failure) Dr J. Taylor, Consultant Cardiologist

More information

Incorporating KT Concepts within Clinical Trials

Incorporating KT Concepts within Clinical Trials Incorporating KT Concepts within Clinical Trials The RELY-ABLE Trial as an Example Stuart Connolly & Robby Nieuwlaat Background - Dabigatran RE-LY Atrial fibrillation (AF) patients at high risk for stroke

More information

Dysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics

Dysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise

More information

Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie

Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow

More information

Atrial Fibrillation and Heart failure

Atrial Fibrillation and Heart failure Atrial Fibrillation and Heart failure and a bit about anticoagulation Tim Sutton, Consultant Cardiologist Middlemore Hospital, Manukau City and Auckland Heart Group Why Does AF Cause Heart Failure Impaired

More information

4/27/2015. Cardiac Events #1 cause of postoperative complications/ mortality- CHF, complete heart block, MI,

4/27/2015. Cardiac Events #1 cause of postoperative complications/ mortality- CHF, complete heart block, MI, Not intended for medical clearance Identify, document, and evaluate health conditions Medication Management Stratify Risks Optimize conditions within context of surgical illness Recommend measures that

More information

HEART FAILURE: PHARMACOTHERAPY UPDATE

HEART FAILURE: PHARMACOTHERAPY UPDATE HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis

More information

Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France

Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage

More information

Dr Chris Ellis. Consultant Cardiologist Auckland City Hospital Auckland

Dr Chris Ellis. Consultant Cardiologist Auckland City Hospital Auckland Dr Chris Ellis Consultant Cardiologist Auckland City Hospital Auckland 8:30-9:25 WS #189: Anticoagulation in AF 9:35-10:30 WS #201: Anticoagulation in AF (Repeated) Anticoagulation in Atrial Fibrillation

More information

Pre-op Risk Assessment. Hal Blanks MD FACC

Pre-op Risk Assessment. Hal Blanks MD FACC Pre-op Risk Assessment Hal Blanks MD FACC Objectives: Identify and manage patients with known or suspected CAD and other cardiac diseases who are at risk of cardiac complications during noncardiac surgery.

More information

AF Diagnosis. Incorporated into over 75 health checks and Public Health Checks

AF Diagnosis. Incorporated into over 75 health checks and Public Health Checks AF Diagnosis Incpated into over 75 health checks and Public Health Checks Pulse Feel the pulse in all >65yrs If irregular do a 12 Lead ECG with Rhythm strip Check Thyroid and FBC and heart rate Refer to

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

New Hypertension Guidelines. Kofi Osei, MD

New Hypertension Guidelines. Kofi Osei, MD New Hypertension Guidelines Kofi Osei, MD None Disclosures Objectives The new blood pressure definitions and cardiovascular risk The role to time and location in the diagnosis of hypertension Apply evidence-based

More information

Clinical Controversies in Perioperative Medicine

Clinical Controversies in Perioperative Medicine Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Predicting & Managing Cardiac Risk A 70-y.o. man with progressive

More information

Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de

Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with

More information

Dobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies

Dobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies Dobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies Mitral Regurgitation The New ASE Guidelines: Role of 2D/3D and CMR William A. Zoghbi MD, FASE, MACC Professor and

More information

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia 6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac

More information

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated) Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor

More information

Common Codes for ICD-10

Common Codes for ICD-10 Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified

More information

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI) Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension

More information

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation

More information

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular

More information

The Atrial Fibrillation Clinic in Llanelli. Dr Lena Marie Izzat Consultant Cardiovascular Physician

The Atrial Fibrillation Clinic in Llanelli. Dr Lena Marie Izzat Consultant Cardiovascular Physician The Atrial Fibrillation Clinic in Llanelli Dr Lena Marie Izzat Consultant Cardiovascular Physician Llanelli Multidisciplinary AF Clinic Went live January 2009 Based on the fact that Carmarthenshire has

More information

t. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines.

t. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines. Name or Policy: Policy Number: 3364-133-116 Department: Approving Officer: Responsible Agent: cope: x Management of Anticoagulation with Invasive Procedures Pharmacy Chief Operating Officer Director of

More information

Condition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9

Condition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9 Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material

More information

To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin

To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin Omprakash Pansara, MD Brian Kline, MD St. Joseph s Health Family Medicine Residency Program, Syracuse, NY Case 75yr old male, who

More information

Innovations in AF Management

Innovations in AF Management Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as

More information

Aha blood pressure guidelines 2016 chart. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Aha blood pressure guidelines 2016 chart. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Search for: Search Search Aha blood pressure guidelines 2016 chart Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu 10-2-2012 Here we explain what blood pressure is, how it is measured, and

More information

Show Me the Outcomes!

Show Me the Outcomes! Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October

More information

Atrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation

Atrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation The (S)Low-down on Rapid Afib Resuscitation 2017 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN Atrial Fibrillation

More information

L. Fauchier (1), S. Taillandier (1), I. Lagrenade (1), C. Pellegrin (1), L. Gorin (1), A. Bernard (1), B. Rauzy (1), D. Babuty (1), GYL.

L. Fauchier (1), S. Taillandier (1), I. Lagrenade (1), C. Pellegrin (1), L. Gorin (1), A. Bernard (1), B. Rauzy (1), D. Babuty (1), GYL. Prognosis in patients with atrial fibrillation and CHA 2 DS 2 VASc score=0 in a real world community based cohort study: Loire Valley Atrial Fibrillation project L. Fauchier (1), S. Taillandier (1), I.

More information

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial

More information

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER: ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to

More information

NEWLY DETECTED ATRIAL FIBRILLATION. Edgar S. Carell, M.D. Director, Vascular Medicine Clinic West Suburban Cardiology

NEWLY DETECTED ATRIAL FIBRILLATION. Edgar S. Carell, M.D. Director, Vascular Medicine Clinic West Suburban Cardiology NEWLY DETECTED ATRIAL FIBRILLATION Edgar S. Carell, M.D. Director, Vascular Medicine Clinic West Suburban Cardiology 68 y/o woman complains of - generalized fatigue - mild DOE - never eats but keeps gaining

More information

Thrombosis Canada Clinical Tools. Perioperative Management of Anticoagulants Antithrombotic Use in Atrial Fibrillation

Thrombosis Canada Clinical Tools. Perioperative Management of Anticoagulants Antithrombotic Use in Atrial Fibrillation Thrombosis Canada Clinical Tools Perioperative Management of Anticoagulants Antithrombotic Use in Atrial Fibrillation Dr. Benjamin Bell, MD FRCPC Staff General Internist North York General Hospital Lecturer,

More information

Objectives. Falling Down on Warfarin Therapy. CHADS 2 Score. CHADS 2 & CHA 2 DS 2 -VASc Score. HAS-BLED Score 04/08/2014. Real World Application

Objectives. Falling Down on Warfarin Therapy. CHADS 2 Score. CHADS 2 & CHA 2 DS 2 -VASc Score. HAS-BLED Score 04/08/2014. Real World Application Falling Down on Warfarin Therapy David Andrew Jacob, PharmD Pharmacy Resident 2013-2014 Dayton VA Medical Center Dayton, Ohio Objectives Describe CHADS 2 score and the decision to anticoagulate patients

More information

심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation

심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation 소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE

More information

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the

More information

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical

More information

2016 General Practice/Family Practice Preferred Specialty Measure Set

2016 General Practice/Family Practice Preferred Specialty Measure Set 1 0059 5 0081 41 N/A 50 N/A 65 0069, EHR 66 0002, EHR Effective Clinical Care Effective Clinical Care Effective Clinical Care Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%): Percentage of patients

More information

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)

More information

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. 1 Phar6122: CV section Date: 3/10/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In

More information

Acta Orthopaedica 2016; 87 (Id.no 10437) Supplementary article data (1/5)

Acta Orthopaedica 2016; 87 (Id.no 10437) Supplementary article data (1/5) Acta Orthopaedica 2016; 87 (Id.no 10437) Supplementary article data (1/5) Supplementary article data Thromboembolic and major bleeding events in relation to perioperative bridging of vitamin K antagonists

More information

SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL

SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 1/17 QOF ID 17/18 QOF ID NICE ID Indicator wording

More information

VanderbiltEM.com. Atrial Fibrillation Update Don t Miss a Beat ACEP AFib. 20 Facts on Atrial Fibrillation in 20 minutes

VanderbiltEM.com. Atrial Fibrillation Update Don t Miss a Beat ACEP AFib. 20 Facts on Atrial Fibrillation in 20 minutes Atrial Fibrillation Update Don t Miss a Beat ACEP 2015 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN VanderbiltEM.com

More information

MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT. Irene Frantzis P year, SGUL Sheba Medical Center

MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT. Irene Frantzis P year, SGUL Sheba Medical Center MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT Irene Frantzis P year, SGUL Sheba Medical Center MITRAL VALVE DISEASE Mitral Valve Regurgitation Mitral Valve Stenosis Mitral Valve Prolapse MITRAL REGURGITATION

More information

17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE

17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE SUMMARY OF CHANGES TO QOF 2018/19 - ENGLAND 18-19 QOF005 KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 17/18 QOF ID 18/19 QOF ID NICE ID Indicator

More information

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation

More information

Summary of Research and Writing Activities In Cardiovascular Disease

Summary of Research and Writing Activities In Cardiovascular Disease Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts

More information

Asif Serajian DO FACC FSCAI

Asif Serajian DO FACC FSCAI Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac

More information

Dual Antiplatelet Therapy Made Practical

Dual Antiplatelet Therapy Made Practical Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation

More information

Coronary Heart Disease. Iqbal Malik

Coronary Heart Disease. Iqbal Malik Coronary Heart Disease Iqbal Malik Pathophysiology IHD Case chest pain Question -interactive What is the result of the exercise test? 1. negative 2. positive 3. equivocal 4. other Q2 answer STEMI! What

More information

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Atrial Fibrillation and Heart Failure: A Cause or a Consequence Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November

More information

14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE

14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes

More information

AF stroke prevention in the Canadian context

AF stroke prevention in the Canadian context AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network

More information

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011 Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite

More information

Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD)

Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) 2. Welcome by Stacey Sheridan, MD, MPH Hello. My name is Stacey Sheridan, and I m here as your partner in Heart Health Now. The North

More information

CARDIAC REHABILITATION PROGRAMME:- MEDICATION

CARDIAC REHABILITATION PROGRAMME:- MEDICATION CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to

More information

Conflict Disclosures. Vermont Cardiac Network. Outline. Series Learning Objectives 4/27/2016. Scott E. Friedman April 28, 2016

Conflict Disclosures. Vermont Cardiac Network. Outline. Series Learning Objectives 4/27/2016. Scott E. Friedman April 28, 2016 Conflict Disclosures Vermont Cardiac Network The Speaker has reported no significant financial relationship with any companies whose product may be germane to the content of their presentations or who

More information

Alex versus Xience Registry Preliminary report

Alex versus Xience Registry Preliminary report Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor

More information

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa

More information

Case Discussion. 18 th Annual UCSD Heart Failure Symposium

Case Discussion. 18 th Annual UCSD Heart Failure Symposium Case Discussion 18 th Annual UCSD Heart Failure Symposium In your office today is a returning patient and an eager-to-please 3 rd year medical student. You review HF s history as the student is in the

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY

More information